| . | Low UCEIS . | High UCEIS . |
|---|---|---|
| Number of patients | 24 | 16 |
| Gender [% female] | 58 | 56 |
| Age, median [range], years | 42 [17–62] | 37 [22–56] |
| Body mass index, median [range] | 25.0 [18.7–37.1] | 23.1 [18.7–31] |
| Disease duration, median [range], years | 7 [0.1–46] | 4 [0.1–18] |
| Time between sigmoidoscopy, median [range], months | 6 [5–7] | 5 [5–7] |
| Proctitis/left-sided colitis/extensive colitis, % | 17/29/50 | 25/50/19 |
| Co-morbidities: none/present [%] Total patient numbers with co-morbidity [n] | 63/37 2 Osteoarthritis 2 Inflammatory arthritis 2 Hypertension 1 Increased cholesterol 1 Foraminal stenosis 1 Depression | 81/19 1 Osteoarthritis 1 Hypertension 1 Primary sclerosing cholangitis |
| Never smoked,/ex-smoker/current smoker, % | 46/50/4 | 69/31/0 |
| Nil medications, % | 4 | 6 |
| Topical 5-ASA, % | 21* | 56 |
| Topical steroid, % | 4 | 13 |
| Oral 5-ASA, % | 54* | 81 |
| Oral steroid, % | 17 | 19 |
| Immune suppressant, % | 29 | 19 |
| Anti-TNF, % | 13 | 6 |
| Vedolizumab, % | 17 | 25 |
| Cyclosporin, % | 4 | 0 |
| Probiotics, % | 0 | 0 |
| . | Low UCEIS . | High UCEIS . |
|---|---|---|
| Number of patients | 24 | 16 |
| Gender [% female] | 58 | 56 |
| Age, median [range], years | 42 [17–62] | 37 [22–56] |
| Body mass index, median [range] | 25.0 [18.7–37.1] | 23.1 [18.7–31] |
| Disease duration, median [range], years | 7 [0.1–46] | 4 [0.1–18] |
| Time between sigmoidoscopy, median [range], months | 6 [5–7] | 5 [5–7] |
| Proctitis/left-sided colitis/extensive colitis, % | 17/29/50 | 25/50/19 |
| Co-morbidities: none/present [%] Total patient numbers with co-morbidity [n] | 63/37 2 Osteoarthritis 2 Inflammatory arthritis 2 Hypertension 1 Increased cholesterol 1 Foraminal stenosis 1 Depression | 81/19 1 Osteoarthritis 1 Hypertension 1 Primary sclerosing cholangitis |
| Never smoked,/ex-smoker/current smoker, % | 46/50/4 | 69/31/0 |
| Nil medications, % | 4 | 6 |
| Topical 5-ASA, % | 21* | 56 |
| Topical steroid, % | 4 | 13 |
| Oral 5-ASA, % | 54* | 81 |
| Oral steroid, % | 17 | 19 |
| Immune suppressant, % | 29 | 19 |
| Anti-TNF, % | 13 | 6 |
| Vedolizumab, % | 17 | 25 |
| Cyclosporin, % | 4 | 0 |
| Probiotics, % | 0 | 0 |
All 40 patients in the study cohort are included. *Significant difference in distribution [chi-squared, p < 0.05]. 5-ASA, 5-aminosalicylic acid; TNF, tumour necrosis factor.
| . | Low UCEIS . | High UCEIS . |
|---|---|---|
| Number of patients | 24 | 16 |
| Gender [% female] | 58 | 56 |
| Age, median [range], years | 42 [17–62] | 37 [22–56] |
| Body mass index, median [range] | 25.0 [18.7–37.1] | 23.1 [18.7–31] |
| Disease duration, median [range], years | 7 [0.1–46] | 4 [0.1–18] |
| Time between sigmoidoscopy, median [range], months | 6 [5–7] | 5 [5–7] |
| Proctitis/left-sided colitis/extensive colitis, % | 17/29/50 | 25/50/19 |
| Co-morbidities: none/present [%] Total patient numbers with co-morbidity [n] | 63/37 2 Osteoarthritis 2 Inflammatory arthritis 2 Hypertension 1 Increased cholesterol 1 Foraminal stenosis 1 Depression | 81/19 1 Osteoarthritis 1 Hypertension 1 Primary sclerosing cholangitis |
| Never smoked,/ex-smoker/current smoker, % | 46/50/4 | 69/31/0 |
| Nil medications, % | 4 | 6 |
| Topical 5-ASA, % | 21* | 56 |
| Topical steroid, % | 4 | 13 |
| Oral 5-ASA, % | 54* | 81 |
| Oral steroid, % | 17 | 19 |
| Immune suppressant, % | 29 | 19 |
| Anti-TNF, % | 13 | 6 |
| Vedolizumab, % | 17 | 25 |
| Cyclosporin, % | 4 | 0 |
| Probiotics, % | 0 | 0 |
| . | Low UCEIS . | High UCEIS . |
|---|---|---|
| Number of patients | 24 | 16 |
| Gender [% female] | 58 | 56 |
| Age, median [range], years | 42 [17–62] | 37 [22–56] |
| Body mass index, median [range] | 25.0 [18.7–37.1] | 23.1 [18.7–31] |
| Disease duration, median [range], years | 7 [0.1–46] | 4 [0.1–18] |
| Time between sigmoidoscopy, median [range], months | 6 [5–7] | 5 [5–7] |
| Proctitis/left-sided colitis/extensive colitis, % | 17/29/50 | 25/50/19 |
| Co-morbidities: none/present [%] Total patient numbers with co-morbidity [n] | 63/37 2 Osteoarthritis 2 Inflammatory arthritis 2 Hypertension 1 Increased cholesterol 1 Foraminal stenosis 1 Depression | 81/19 1 Osteoarthritis 1 Hypertension 1 Primary sclerosing cholangitis |
| Never smoked,/ex-smoker/current smoker, % | 46/50/4 | 69/31/0 |
| Nil medications, % | 4 | 6 |
| Topical 5-ASA, % | 21* | 56 |
| Topical steroid, % | 4 | 13 |
| Oral 5-ASA, % | 54* | 81 |
| Oral steroid, % | 17 | 19 |
| Immune suppressant, % | 29 | 19 |
| Anti-TNF, % | 13 | 6 |
| Vedolizumab, % | 17 | 25 |
| Cyclosporin, % | 4 | 0 |
| Probiotics, % | 0 | 0 |
All 40 patients in the study cohort are included. *Significant difference in distribution [chi-squared, p < 0.05]. 5-ASA, 5-aminosalicylic acid; TNF, tumour necrosis factor.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
